ODC1 Genotype-Guided DFMO and Sulindac Therapy for Carcinoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer chemoprevention methods face challenges due to marginal agent efficacy and toxicities, and there is a need for effective and less toxic treatments for colorectal cancers, particularly in identifying suitable treatment regimes for patients based on genetic markers.
Innovation Solution
A method involving genetic testing to determine a patient's ODC1 allele genotype at specific positions, followed by administering a combination of α-difluoromethylornithine (DFMO) and a non-aspirin containing NSAID, such as sulindac, to inhibit ornithine decarboxylase and modulate the polyamine pathway, thereby preventing or treating carcinoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polyamine-inhibitory combination therapy (DFMO and sulindac) is administered to colorectal adenoma patients, then adenoma prevention efficacy is improved, but ototoxicity and cardiovascular events increase
Solution Approach 1:
The patent applies local quality by tailoring the treatment regimen to each patient's specific ODC1 genotype. Patients with the AA genotype receive the full DFMO and sulindac combination therapy, while patients with the GG genotype receive alternative treatments. This genotype-specific approach ensures that only patients who will benefit from the therapy receive it, eliminating ototoxicity and cardiovascular events in patients who would not respond to treatment.
2Adaptability or versatility
If ODC1 genotype testing is implemented to guide treatment selection, then treatment suitability identification is improved, but diagnostic complexity increases
Solution Approach 1:
The patent extracts the critical decision-making factor (ODC1 genotype status) from the complex diagnostic process. By focusing solely on genotyping at position +263 of the ODC1 gene, the system isolates the single most important predictor of treatment response, eliminating the need for complex multi-parameter assessments and simplifying the diagnostic workflow to a single, actionable test.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively prevents the formation of new aberrant crypt foci, adenomatous polyps, and adenomas, and identifies suitable patients for treatment, reducing toxicity and improving treatment efficacy.
Implementation Method 1
a first agent that inhibits ornithine decarboxylase (ODC) within the patient
Implementation Method 2
a second agent that modulates the polyamine pathway to reduce overall polyamine content within the patient when combined with the first agent
Implementation Method 3
the second agent may also increase the expression of spermidine/spermine N1-acetyltransferase within the patient
Data Source
AI summary
The present invention provides methods and kits a) for preventing and/or treating cancer (e.g., colorectal cancer, neuroblastoma) that is linked, in part, to high levels of ODC activity and increased cellular polyamine content, b) for predicting cancer patient survival, especially cancer patient's whose cancer is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and c) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at positions +263 and/or +316 of the ODC1 gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 genotype at the +263 and/or +316 positions, as a means to guide treatment selection.